tiprankstipranks
Trending News
More News >

Legend Biotech price target lowered to $54 from $60 at UBS

UBS analyst Ashwani Verma lowered the firm’s price target on Legend Biotech (LEGN) to $54 from $60 and keeps a Buy rating on the shares. UBS continue to see upside to Legend Biotech stock, but the upside is based on modest growth in Q2, with an acceleration in the second half of 2025, the analyst tells investors in a research note. The stock may continue to be range-bound unless there is a material step-up in the revenue profile of Carvykti, UBS contends.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1